Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 26;9(5):107-110.
doi: 10.1002/cld.633. eCollection 2017 May.

Update on primary sclerosing cholangitis

Roger W Chapman  1   2
Affiliations
Review

Update on primary sclerosing cholangitis

Roger W Chapman. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Factors involved in the pathogenesis of PSC.
Figure 2
Figure 2
Algorithm for UDCA use in PSC, as proposed by Tabibian and Lindor.10
Figure 3
Figure 3
Schematic representation of the various elements contributing to the pathophysiology of PSC (in colored boxes) and the therapeutic agents (listed above) that may be directed against this particular element. Agents in italics are still in development and are not licensed.7 Abbreviations: atRA, all‐trans retinoic acid; BA, bile acid; BE, biliary epithelium; CFTR, cystic fibrosis transmembrane conductance; MDR3, multidrug resistance 3 gene; PAMP, pathogen‐associated molecular patterns; PL, phospholipid; SXR, steroid and xenobioticsensing nuclear receptor; TGR5, G protein‐coupled receptor; TLR, Toll‐like receptors; VAP is vascular adhesion protein.
See this image and copyright information in PMC

References

    1. Williamson KD, Chapman RW. Primary sclerosing cholangitis: a clinical update. Brit Med Bull 2015;114:53–64. - PubMed
    1. Chapman RW. Malignancy in PSC: bile duct, liver and colon. Clin Liver Dis 2014;3:83–85. - PMC - PubMed
    1. Boonstra KB, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, et al.; EpiPSCPBC Study Group . Population‐based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045–2055. - PubMed
    1. Hirschfield GM, Chapman RW, Karlesen TH, Lammert F, Lazaridis KN, Mason AL. The genetics of complex cholestatic disorders. Gastroenterology 2013;144:1357–1374. - PMC - PubMed
    1. Ji SG, Juran BD, Mucha S, Folseras T, Jostins L, Melum E, et al. Genome‐wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nat Genet 2017;49:269–273. - PMC - PubMed